Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 801–900 of 1,002
Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
Tsakaneli, A., & Williams, O. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.741413 · Cited by 19
“Even though the cost has increased with time, and scientific and technological factors ought to make the process of drug development faster and more efficient, the number of drugs approved every year per USD spent on development has halved roughly every 9 years since the 1950s (Munos, 2009; Scannell et al., 2012; Nose…”
BackgroundDurdağı, S., Orhan, M. D., Aksoydan, B., Calis, S., Başar, B. D., Şahin, K., Shahraki, A., İyison, N. B., & Avşar, T. (2021) · Molecular Informatics · doi:10.1002/minf.202100062 · Cited by 16
Introduction and Historical Overview of Drug Repurposing Opportunities
Pushpakom, S. P. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839163401-00001 · Cited by 22
Karwasra, R., Khanna, K., Singh, S., Ahmad, S., & Verma, S. M. (2022) · Studies in computational intelligence · doi:10.1007/978-981-16-9221-5_21 · Cited by 21
Contemporary Trends in the Development of the Pharmaceutical Industry in the World
Dorocki, S. (2014) · Studies of the Industrial Geography Commission of the Polish Geographical Society · doi:10.24917/20801653.25.6 · Cited by 16
Opening the door to innovation
Schuurman, J., Graus, Y., Labrijn, A. F., Ruuls, S. R., & Parren, P. W. H. I. (2014) · mAbs · doi:10.4161/mabs.29004 · Cited by 16
“With costs soaring, the number of US Food and Drug Administration (FDA)approved drugs per dollar spent steadily declined between the 1950s and 2010s.(4,5) Several factors may have contributed to this apparent decrease in productivity, such as an increased regulatory focus on patient safety and cost-benefit, limited po…”
BackgroundCantu, D. A., & Kao, W. J. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201300063 · Cited by 17
Big Data: Challenge and Opportunity for Translational and Industrial Research in Healthcare
Rossi, R. L., & Grifantini, R. (2018) · Frontiers in Digital Humanities · doi:10.3389/fdigh.2018.00013 · Cited by 16
“Securing FDA approval of a repurposed drug costs only $40–$80million in total, compared to the average of $1–$2 billion it takes to develop a new drug (Scannell et al., 2012).”
BackgroundThe Dynamics of Pharmaceutical Regulation and R&D Investments
Levaggi, R., Moretto, M., & Pertile, P. (2016) · Journal of Public Economic Theory · doi:10.1111/jpet.12195 · Cited by 16
Ward, D. J., Doos, L., & Stevens, A. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027625 · Cited by 16
“These costs have risen over time for a number of reasons, including the increasing complexity and length of clinical trial programmes to meet the needs of regulators and HTA bodies, so that, by some estimates, the rate of new drug launches per R&D spend has fallen by around a half every 9 years since the 1950s.(40) Ho…”
BackgroundEngineering Tissues from Induced Pluripotent Stem Cells
Loskill, P., & Huebsch, N. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2019.0118 · Cited by 16
Nanomedicine Beyond Tumor Passive Targeting: What Next?
Longo, J. P. F., & Muehlmann, L. A. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0208 · Cited by 16
Drug Gene-Set Analysis Identifies Established and Emerging Therapeutic MechanismsPreprint
Bell, N. Y., Uffelmann, E., van Walree, E. S., Schipper, M., Heilbron, K., de Leeuw, C., & Posthuma, D. (2022) · medRxiv · doi:10.1101/2022.09.06.22279660 · Cited by 16
Developments and challenges in hit progression within fragment-based drug discovery
Grosjean, H., & Biggin, P. C. (2026) · Nature Communications · doi:10.1038/s41467-026-68941-z · Cited by 17
Exceptional Repositioning of Dog Dewormer: Fenbendazole Fever
Sultana, T., Jan, U., Lee, H., Lee, H., & Lee, J. I. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100338 · Cited by 15
Li, S., Liu, Y., Liu, M., Wang, L., & Li, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1013803 · Cited by 15
“Drug discovery is a time-consuming, costly, and complex process (Overington et al., 2006; Scannell et al., 2012).”
BackgroundJung, H., Hwang, J., & Kim, E. (2023) · Journal of Engineering and Technology Management · doi:10.1016/j.jengtecman.2023.101781 · Cited by 15
Sonosensitive Cavitation Nuclei—A Customisable Platform Technology for Enhanced Therapeutic Delivery
Lyons, B., Balkaran, J. P. R., Dunn-Lawless, D. M., Lucian, V. M., Keller, S. B., O’Reilly, C. S., Hu, L., Rubasingham, J., Nair, M., Carlisle, R. C., et al. (2023) · Molecules · doi:10.3390/molecules28237733 · Cited by 15
Biomarker use is Associated with Reduced Clinical Trial Failure Risk in Metastatic Melanoma
Rubinger, D. A., Hollmann, S., Serdetchnaia, V., Ernst, D. S., & Parker, J. L. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.80 · Cited by 15
Xu, Y., & Li, Z. (2019) · Medicinal Research Reviews · doi:10.1002/med.21566 · Cited by 15
“Such information can play an important role for effective decision‐making in the pharmaceutical industry.(44,52) Furthermore, the noninvasiveness nature of PET technology allows longitudinal studies and intra‐animal comparison with significant reduced numbers of animals in comparison with other preclinical screening t…”
ResultStaroseletz, Y., Amirloo, B., Williams, A., Lomzov, A. A., Burusco, K. K., Clarke, D. J., Brown, T. P., Аркадьевна, З. М., & Bichenkova, E. V. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa780 · Cited by 15
“Contrary to small-molecule drug chemotherapeutic treatments, which suffer from cytotoxicity, with inevitable side effects which limit their success, (4,5) RNA therapeutics offer the opportunity of high selectivity, improved potency and reduced toxicity (6).”
BackgroundSources of innovation for new medicines: questions of sustainability
Kinch, M. S., Kraft, Z., & Schwartz, T. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.026 · Cited by 15
Járomi, L., Csöngei, V., Vesel, M., Abdelwahab, E. M. M., Soltani, A., Torok, Z., Smuk, G., Sárosi, V., & Pongracz, J. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105384 · Cited by 17
Recycled Translation: Repurposing Drugs for Stroke
Spellicy, S. E., & Hess, D. C. (2022) · Translational Stroke Research · doi:10.1007/s12975-022-01000-z · Cited by 17
“Alternatively, studies utilizing data over larger time frames have found more narrow estimates of $2–3 billion per new compound [18, 19].”
BackgroundProfitability and drug discovery
Işık, E., & Orhangazi, Ö. (2022) · Industrial and Corporate Change · doi:10.1093/icc/dtac011 · Cited by 15
Atkins, M. B., Abu‐Sbeih, H., Ascierto, P. A., Bishop, M., Chen, D. S., Dhodapkar, M. V., Emens, L. A., Ernstoff, M. S., Ferris, R. L., Greten, T. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005413 · Cited by 15
Repurposing Vitamin D as an Anticancer Drug
Gilbert, D. C., Vale, C. L., Haire, R., Coyle, C., & Langley, R. E. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.10.004 · Cited by 15
“Repurposing drugs as anticancer therapeutics could shorten the conventional investigational pathway and open multiple new avenues of investigation [1].”
BackgroundIncorporation of Rapid Thermodynamic Data in Fragment-Based Drug Discovery
Kobe, A., Caaveiro, J. M. M., Tashiro, S., Kajihara, D., Kikkawa, M., Mitani, T., & Tsumoto, K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301603n · Cited by 17
Schneider, U., Friedli, T. K., Basu, P., & Werani, J. (2015) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-014-9210-5 · Cited by 15
“In the last 60 years, the number of drugs approved per billion dollars spent on R&D has halved approximately every 9 years [13].”
BackgroundLate-stage pharmaceutical R&D and pricing policies under two-stage regulation
Jobjörnsson, S., Förster, M., Pertile, P., & Burman, C. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.06.002 · Cited by 15
“…expenditure growth, suppliers of innovations have witnessed a substantial reduction in the number of new drugs approved per billion of US dollars spent on R&D (Scannell et al., 2012; Pammolli et al., 2011) and an increase in the average cost of development of a new drug (DiMasi et al., 2003, 2016).”
Cells and Organs on Chip—A Revolutionary Platform for Biomedicine
Joshi, P. N. (2016) · InTech eBooks · doi:10.5772/64102 · Cited by 18
Strategic R&D transactions in personalized drug development
Makino, T., Lim, Y., & Kodama, K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.03.009 · Cited by 15
Basalla, J. L., Harris, R., Burgess, E., Zeedyk, N., & Wildschutte, H. (2020) · FEMS Microbiology Letters · doi:10.1093/femsle/fnaa018 · Cited by 15
Improving Access to Medicines in Low‐Income Countries: A Review of Mechanisms
Bors, C., Christie, A. F., Gervais, D. J., & Clayton, E. W. (2015) · The Journal of World Intellectual Property · doi:10.1111/jwip.12032 · Cited by 15
Anaerobes as Sources of Bioactive Compounds and Health Promoting Tools
Mamo, G. (2016) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2016_6 · Cited by 16
Janero, D. R. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.685154 · Cited by 15
“As a reflection of acquisition mania, outsourcing to contract research organizations, and big-pharma involvement in start-up/venture investments (among other factors), the well-established trend of shrinking preclinical drug-discovery research within pharmaceutical companies shows no sign of abating [1,4].”
BackgroundRegenerative Medicine: Transforming the Drug Discovery and Development ParadigmPreprint
Karathanasis, S. K. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014084 · Cited by 15
“…# 2014 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a014084 Cite this article as Cold Spring Harb Perspect Med 2014;4:a014084 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg ism” to deliver solutions to complex biological problems (Scannell et al. 2012).”
BackgroundInfluentialNishida, Y., Kodama, K., & Sengoku, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103429 · Cited by 14
Computer-aided drug repurposing to tackle antibiotic resistance based on topological data analysis
Tarín-Pelló, A., Suay‐García, B., Forés-Martos, J., Falcó, A., & Pérez‐Gracia, M. T. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107496 · Cited by 14
Morais, W. D. A., de Souza, J. G., García‐Villén, F., Loureiro, J. L., Raffin, F. N., Fernandes, M. A. C., Souto, E. B., Severino, P. B., & Barbosa, R. D. M. (2024) · World Journal of Pediatrics · doi:10.1007/s12519-024-00834-x · Cited by 14
“The total development time for new drugs takes at least 13 to 15 years [117, 118].”
Sun, D., Macedonia, C. R., Chen, Z., Chandrasekaran, S., Najarian, K., Zhou, S. Y., Cernak, T., Ellingrod, V. L., Jagadish, H. V., Marini, B. L., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01684 · Cited by 15
Pharma innovation: how evolutionary economics is shaping the future of pharma R&D
Schuhmacher, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104222 · Cited by 14
Improving productivity of modern-day drug discovery
Breyer, M. D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.870150 · Cited by 14
“While the number of new molecular entities launched per year has gradually decreased [2], over the past six decades, the cost of launching a drug has doubled every 9 years in inflation adjusted dollars [3].”
BackgroundBiological Networks and Drug Discovery—Where Do We Stand?
Geppert, T., & Koeppen, H. (2014) · Drug Development Research · doi:10.1002/ddr.21207 · Cited by 16
Egner, J. M., Jensen, D. R., Olp, M. D., Kennedy, N. W., Volkman, B. F., Peterson, F. C., Smith, B. C., & Hill, R. B. (2017) · ChemBioChem · doi:10.1002/cbic.201700386 · Cited by 14
Karp, F., Turino, L. N., Estenoz, D. A., Castro, G. R., & Islan, G. A. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101241 · Cited by 14
Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study
Bolelli, K., Ertan‐Bolelli, T., Ünsalan, O., & Altunayar‐Unsalan, C. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129449 · Cited by 14
Babayeva, M., & Loewy, Z. G. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s275964 · Cited by 14
SPP-CPI: Predicting Compound–Protein Interactions Based On Neural Networks
Qian, Y., Li, X., Zhang, Q., & Zhang, J. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3084397 · Cited by 14
“The interaction analysis technique based on the experiment is expensive and time-consuming [2], so it’s very meaningful to study the computing method to identify the relationship between compound and protein.”
MethodDrug repositioning of polaprezinc for bone fracture healing
Ko, E. A., Park, Y. J., Yoon, D. S., Lee, K., Kim, J., Jung, S., Lee, J. W., & Park, K. H. (2022) · Communications Biology · doi:10.1038/s42003-022-03424-7 · Cited by 14
Identifying and Mitigating Potential Biases in Predicting Drug Approvals
Xu, Q., Ahmadi, E., Amini, A., Rus, D. L., & Lo, A. W. (2022) · Drug Safety · doi:10.1007/s40264-022-01160-9 · Cited by 14
Wang, M., Luo, Y., Zhao, H., Zhang, Y., Zhang, D., & Zhang, X. (2023) · ACS Catalysis · doi:10.1021/acscatal.3c03578 · Cited by 14
Determining Physical Principles of Subcellular Organization
Needleman, D., & Jan Brugués, A. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.04.018 · Cited by 14
“In the past 60 years, the amount of money spent on drug research and development has skyrocketed while the success rates of these efforts have plummeted, causing widespread concern for the viability of the industry (Scannell et al., 2012).”
BackgroundReflection of successful anticancer drug development processes in the literature
Heinemann, F., Huber, T., Meisel, C., Bundschus, M., & Leser, U. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.008 · Cited by 14
Loesche, A., Wiese, J., Sommerwerk, S., Simon, V., Brandt, W., & Csük, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.051 · Cited by 14
Do large mergers increase or decrease the productivity of pharmaceutical R&D?
Ringel, M. S., & Choy, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.002 · Cited by 14
Michelet, B., Carreyre, H., Lecornué, F., Martin‐Mingot, A., & Thibaudeau, S. (2018) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2018.04.017 · Cited by 14
Ohnesorge, N., Sasore, T., Hillary, D., Álvarez, Y., Carey, M., & Kennedy, B. N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00508 · Cited by 14
Redefining the research hospital
Nachev, P., Herron, D., McNally, N., Rees, G. E., & Williams, B. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0201-2 · Cited by 14
Joshi, K., & Patil, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801814-9.00009-x · Cited by 14
Multiscale Virtual Screening Optimization for Shotgun Drug Repurposing Using the CANDO Platform
Hudson, M. L., & Samudrala, R. (2021) · Molecules · doi:10.3390/molecules26092581 · Cited by 16
The development speed paradox: can increasing development speed reduce R&D productivity?
Lendrem, D. W., & Lendrem, C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.002 · Cited by 14
“Reasons offered include 1) the “low hanging fruit” hypothesis – that the industry has already exploited most of the scientific and technological advances of the 1960’s and 1970’s; 2) the “regulatory hurdles” hypothesis – that higher regulatory hurdles act as barriers to new product introduction; and 3) the “blockbuste…”
BackgroundKinch, M. S., & Moore, R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.05.013 · Cited by 14
“The trends we identified here may suggest that pharmaceutical industry withdrawal from the early stages of drug development was a logical outcome of ‘‘Eroom’s Law’’ (Scannell et al., 2012).”
BackgroundDeveloping the Transdisciplinary Aging Research Agenda: New Developments in Big Data
Callaghan, C. W. (2017) · Current Aging Science · doi:10.2174/1874609810666170719100122 · Cited by 14
Four Lessons from Global Health Drug Discovery: Medicine for an Ailing Industry?
Elliott, R. L. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3002105 · Cited by 14
Metabolically-Driven Maturation of hiPSC-Cell Derived Cardiac ChipPreprint
Huebsch, N., Charrez, B., Siemons, B., Boggess, S. C., Wall, S., Neiman, G., Charwat, V., Jæger, K. H., Cleres, D., Telle, Å., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/485169 · Cited by 16
Challenges and Potential of Using Digital Biomarkers in Healthcare and Clinical Trials
Lieberwirth, J. K., Mittermaier, M., & Stern, A. D. (2026) · Communications Medicine · doi:10.1038/s43856-026-01450-8 · Cited by 13
Wolf, Á., Zsoldos, P., Széll, K., & Galambos, P. (2024) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2024.100168 · Cited by 13
Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs
Xu, S., & Kesselheim, A. S. (2014) · The Journal of Law Medicine & Ethics · doi:10.1111/jlme.12176 · Cited by 13
Holmes, D. I. R. (2016) · Nature · doi:10.1038/533s54a · Cited by 13
Industry–Academic Relationship in a New Era of Drug Discovery
Vallance, P. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4217 · Cited by 13
O’Dwyer, P. J., Box, K. J., Dressman, J., Griffin, B. T., Henze, L. J., Litou, C., Pentafragka, C., Statelova, M., Vertzoni, M., & Reppas, C. I. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaa055 · Cited by 13
Growth contributions of technological change: Is there a burden of knowledge effect?
Callaghan, C. W. (2021) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2021.121076 · Cited by 14
Saeedi, S. A. W., Sharifuddin, J., & Kelly, W. K. S. (2022) · Food Research · doi:10.26656/fr.2017.6(2).211 · Cited by 13
“However, this finding was in contrast with the findings of Scannell et al. (2012), who published that perceived behavioural control did not have a significant impact on intentions.”
ResultCell-free Biosynthesis of Peptidomimetics
Lee, K., Willi, J. A., Cho, N., Kim, I., Jewett, M. C., & Lee, J. (2023) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-022-0268-5 · Cited by 13
“Hence both application and targets are limited, and the number of new small molecule drugs approved yearly has remained constant [43,44].”
Innovation in Therapeutics Development at the NCATS
Colvis, C. M., & Austin, C. P. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.247 · Cited by 13
Heywood, J. J. N., Evangelou, M., Donna, G., Kennet, J., Katerina, A., Guy, C., O’Brien, C., Nutland, S. L., Judy, B., Walker, N. M., et al. (2015) · Trials · doi:10.1186/s13063-015-0583-7 · Cited by 13
“physicians to make clinical observations [37].”
Mas, C., Boda, B., Caul-Futy, M., Huang, S., Wisniewski, L., & Constant, S. (2016) · Alternatives to Laboratory Animals · doi:10.1177/026119291604400509 · Cited by 13
“A likely explanation for this is the lack of relevant preclinical models to properly validate drug candidates and fully characterise their actual efficacy, before engaging in clinical trials (5).”
BackgroundMicrobial Resource Centers Contribute to Bioprospecting of Bacteria and Filamentous Microfungi
Overmann, J., & Smith, D. I. (2016) · Topics in biodiversity and conservation · doi:10.1007/978-3-319-47935-4_4 · Cited by 13
Sensor-free and Sensor-based Heart-on-a-chip Platform: A Review of Design and Applications
Wan, H., Gu, C., Gan, Y., Wei, X., Zhu, K., Hu, N., & Wang, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190207170004 · Cited by 13
Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity
Sameshima, T., Yukawa, T., Hirozane, Y., Yoshikawa, M., Katoh, T., Hara, H., Yogo, T., Miyahisa, I., Okuda, T., Miyamoto, M., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00128 · Cited by 14
Development of a Microfluidic Array to Study Drug Response in Breast Cancer
Virumbrales-Muñoz, M., Livingston, M. K., Farooqui, M. A., Skala, M. C., Beebe, D. J., & Ayuso, J. M. (2019) · Molecules · doi:10.3390/molecules24234385 · Cited by 14
“The average number of new drugs approved by the US Food and Drug Administration (FDA) per year has declined since the 1990s, while costs have steadily increased over the years [1].”
BackgroundIC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
Xu, Y., Páchniková, G., Wang, H., Wu, Y., Przybilla, D., Schäfer, R., Chen, Z., Zhu, S., & Keilholz, U. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.7279 · Cited by 15
Beyond the pill: The move towards value-added services in the pharmaceutical industry
Wenzel, M., Henne, N., & Zöllner, Y. F. (2014) · Journal of Medical Marketing Device Diagnostic and Pharmaceutical Marketing · doi:10.1177/1745790414556564 · Cited by 13
Discontinued anxiolytic drugs (2009 – 2014)
Mandrioli, R., & Mercolini, L. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.998335 · Cited by 14
“The root causes of these trends are probably understandable and well-known, and have been analyzed previously [126]; however, unfortunately, remedies are very difficult to implement or altogether unrealistic (e.”
BackgroundDeng, Z., Tu, W., Deng, Z., & Hu, Q. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00175 · Cited by 13
Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery
Christensen, K., Roudnicky, F., Patsch, C., & Burcin, M. M. (2017) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2017_23 · Cited by 14
An Industry Perspective on Dengue Drug Discovery and Development
Hernández‐Morales, I., & Loock, M. V. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8727-1_23 · Cited by 14
Plant natural fragments, an innovative approach for drug discovery
David, B., Grondin, A., Schambel, P., Vitorino, M., & Zeyer, D. (2019) · Phytochemistry Reviews · doi:10.1007/s11101-019-09612-4 · Cited by 13
Collins, J. M., & Dempsey, M. K. (2019) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2019.09.003 · Cited by 31
Zhavoronkov, A. A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00435 · Cited by 13
Limbu, K. R., Chhetri, R. B., Oh, Y. S., Baek, D. J., & Park, E.-Y. (2022) · Molecules · doi:10.3390/molecules27238127 · Cited by 12
Delaleu, N., Marti, H., Strauss, P., Sekulic, M., Osman, T., Tøndel, C., Skrunes, R., Leh, S. M., Svarstad, E., Nowak, A., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.06.029 · Cited by 12
Yang, Z., Yu, J. Q., & Wong, C. C. (2024) · Cells · doi:10.3390/cells13161312 · Cited by 13
Gordillo‐Marañón, M., Schmidt, A. F., Warwick, A., Tomlinson, C., Ytsma, C. R., Engmann, J., Torralbo, A., Maclean, R., Sofat, R., Langenberg, C., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00625-5 · Cited by 12
Investigating the binding interactions of cetirizine and diphenhydramine in SDS-SDBS mixed micelles
Srivastava, A., Tiwari, S., Khan, J. M., Deb, D. K., & Ullah, M. W. (2025) · Colloid & Polymer Science · doi:10.1007/s00396-025-05400-z · Cited by 12
“The development of novel therapeutic compounds is a complex, expensive, and time-consuming endeavor, often requiring years of research and substantial financial investment [1].”
Machine Learning for De Novo Molecular Generation: A Comprehensive Review
Chen, Y., & Xue, W. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00861 · Cited by 18
Neue chemische Strukturen durch Mikrofluidiksysteme
Rodrigues, T., Schneider, P., & Schneider, G. (2014) · Angewandte Chemie · doi:10.1002/ange.201400988 · Cited by 12
A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Wiley eBooks · doi:10.1002/9783527693405.ch4 · Cited by 12
Facilitating Antiviral Drug Discovery Using Genetic and Evolutionary Knowledge
Xu, X., Zhang, Q., Chu, X., Quan, Y., Lv, B., & Zhang, H. (2021) · Viruses · doi:10.3390/v13112117 · Cited by 12
“Some studies have shown that the efficiency of research and development (R&D) has been steadily declining, as measured by the number of new drugs that are put on the market per billion US dollars of Research and Development expenditure in the global biotechnology and pharmaceutical industries [23,26].”
Background
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.